Health
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine | NEJM – nejm.org
Correspondence from The New England Journal of Medicine — Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
To the Editor
Table 1.
Table 1. Efficacy of BNT162b2 against Covid-19 According to Analysis Period. Polack et al. (Dec. 31)1 report a vaccine efficacy of 94.8% against Covid-19 after two doses of the messenger RNA (mRNA) vaccine BNT162b2 (PfizerBioNTech). The authors also report a vaccine efficacy of 52.4% from after the first dose to before the second dose, but in their calculation, they included data that were collected during the first 2 weeks after the first dose, when immunity would have still…
-
Noosa News10 hours agoMan dies in Brisbane crash, women and girl rushed to hospital
-
General19 hours agoProductivity summit ends day two with progress on rules changes to boost housing supply
-
General20 hours agoSharp rise in airfares push UK inflation higher in July
-
Noosa News24 hours agoBIGSOUND Is Back For 2025 With Over 130 Emerging Artists